濮阳东方妇科口碑高濮阳东方男科医院导航,濮阳东方男科医生怎么样,濮阳东方医院治疗早泄靠谱,濮阳东方看妇科口碑评价很好,濮阳东方看男科好吗,濮阳东方医院男科治疗阳痿口碑放心很好,濮阳东方医院看妇科专业吗

CHANGCHUN, Jan. 22 (Xinhua) -- Chinese Vice President Xi Jinping stressed political integrity as the most important criteria in electing Communist Party cadres, during his three-day inspection tour in northeast Jilin province, which ended Saturday.The standards of political integrity and professional competence, with the former being the most important, should be strictly observed in the upcoming election of the new term for Party Committee members at provincial, city, county and township levels, Xi, a Standing Committee member of the Communist Party of China (CPC) Central Committee Political Bureau, said.During his meeting with leaders of the provincial Party Committee and provincial government of Jilin, Xi said efforts should be made to reinforce the notion of putting people first and exercising the state power for the people among carders.Chinese Vice President Xi Jinping (2nd L front) talks with a staff member at a workshop of FAW car factory in Changchun, capital of northeast China's Jilin Province, Jan. 21, 2011. Xi made an inspection tour in Jilin from Jan. 20 to 22.While visiting a community Party organization, Xi also asked grass-roots Party organizations to give priority to building a closer bond with the public and serving the public.During his visit to several companies, including Changchun-based First Automobile Works, Xi called for efforts to develop technology-intensive industries and the manufacturing of high-end products to promote economic restructuring.He also visited flood-hit areas to observe the relocation of flood victims and reconstruction work. Jilin Province was hit by unprecedented floods last July and August.He asked local governments to rebuild flood-damaged homes as soon as possible and repair those destroyed water conservancy projects and encourage farmers to grow crops on flooded lands.

BEIJING, March 7 (Xinhua) -- The Chinese currency Renminbi (RMB), or the yuan, on Monday strengthened to an all-time high of 6.5651 per U.S. dollar, according to the China Foreign Exchange Trading System.Monday's central parity rate of the RMB against U.S. dollar was 20 basis points lower than the previous record of 6.5671 set on last Friday.The yuan has appreciated 3.84 percent since June 19 last year when the People's Bank of China, the central bank, announced it would further reform the exchange rate formation mechanism to improve its flexibility.On China's foreign exchange spot market, the yuan can rise or fall 0.5 percent from the central parity rate each trading day.The central parity rate of the RMB against the U.S. dollar is based on a weighted average of prices before the opening of the market for each business day.

BEIJING, Feb. 11 (Xinhua) -- China's foreign exchange regulator said Friday it did not suffer any losses from its investment in Fannie Mae and Freddie Mac bonds, adding that media reports of up to 450 billion U.S. dollars of losses were "groundless.""Up until now, the capital and interest repayments of Fannie Mae and Freddie Mac bonds is normal, and no losses have incurred," The State Administration of Foreign Exchange (SAFE) said on its website.Annual yields of the bonds were around 6 percent between 2008 and 2010, the SAFE said.The regulator, which oversees China's more than 2 trillion U.S. dollars of foreign exchange reserve, also clarifies it had not bought any stocks of the two troubled mortgage companies.UPI reported on Friday that the Obama Administration will propose phasing out the two mortgage giants after rescuing them, which is part of a U.S. Treasury Department white paper to Congress that lays out three ways of cutting government support to the 10.6 trillion U.S. dollars mortgage market.

WASHINGTON, March 4 (Xinhua) -- New data suggest that the epilepsy drug Topamax (topiramate) and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration (FDA) said Friday in a statement.Before prescribing topiramate, approved to treat certain types of seizures in people who have epilepsy, health care professionals should warn patients of childbearing age about the potential hazard to the fetus if a woman becomes pregnant while using the drug, the FDA said.Topiramate also is approved to prevent migraine headaches, but not to relieve the pain of migraines."Health care professionals should carefully consider the benefits and risks of topiramate when prescribing it to women of childbearing age," said Russell Katz, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "Alternative medications that have a lower risk of birth defects should be considered."Cleft lip and cleft palate, collectively called oral clefts, are birth defects that occur when parts of the lip or palate do not completely fuse together early in the first trimester of pregnancy, a time when many women do not know they are pregnant.The defects range from a small notch in the lip to a groove that runs into the roof of the mouth and nose, possibly leading to problems with eating, talking, and to ear infections. Surgery often is performed to close the lip and palate and most children do well after treatment.Data from the North American Antiepileptic Drug (AED) Pregnancy Registry indicate an increased risk of oral clefts in infants exposed to topiramate during the first trimester of pregnancy. Infants exposed to topiramate as a single therapy experienced a 1.4 percent prevalence of oral clefts, compared with a prevalence of 0.38 percent - 0.55 percent in infants exposed to other antiepileptic drugs.Infants of mothers who did not have epilepsy and were not being treated with other antiepileptic drugs had a prevalence of 0.07 percent. Similar data from the United Kingdom Epilepsy and Pregnancy Register supported the North American AED Pregnancy Registry data.According to the FDA, before starting topiramate, pregnant women and women of childbearing potential should discuss other treatment options with their health care professional.

JERUSALEM, March 31 (Xinhua) -- Two researchers at the Hebrew University (HU) of Jerusalem have been honored with a prestigious award for their study of the connection between several inflammatory diseases, cancer and bacteria.Medical faculty members, Dr. Eli Pilarsky and Prof. Sigal Ben- Yehuda, won this year's Sir Zelman Cowen Universities Fund prize that recognizes significant achievement in the field of medicine.The prize committee noted the impressive contributions of Pilarsky and Ben-Yehuda in understanding complex diseases like cancer and antibiotic-resistant infections, and, in a first, decided to award the two scientists this year.Pilarsky told Xinhua that his research deals with the connection between chronic inflammatory diseases like hepatitis, and the development of cancer cells."The relevance of this discovery is that we were able to establish the link between the molecules secreted with such inflammations and the proliferation of cancer cells," Pilarsky explained, noting that "we discovered that the inflammation favors the cancer cells' growth, and now we are trying to find a way to manipulate these molecules to stop the cancer cells from appearing. ""The importance of these findings lies in the fact that 20 percent of the world's cancer cases are attributed to inflammation processes," Pilarsky pointed out.